NASDAQ: CRDLCardiol Therapeutics Inc Stock
$1.76-0.01 (-0.56%)
Updated Apr 22, 2024
CRDL Price
$1.76
Fair Value Price
$0.70
Market Cap
$115.02M
52 Week Low
$0.55
52 Week High
$2.17
P/E
-5.43x
P/B
5.54x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$21.15M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.3
Operating Cash Flow
-$19M
Beta
1.44
Next Earnings
May 17, 2024
Ex-Dividend
N/A
Next Dividend
N/A
CRDL Overview
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses developing anti-fibrotic and anti-inflammatory therapies to treat cardiovascular disease. Its lead product is CardiolRx, which reduces cardiovascular and respiratory events in patients hospitalized with COVID-19. The company is also developing a subcutaneous formulation of CardiolRx to treat fibrosis and inflammation that progress to heart failure. Cardiol Therapeutics was incorporated in 2017 and is headquartered in Oakville, Ontario, Canada.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CRDL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CRDL ($1.76) is overvalued by 149.86% relative to our estimate of its Fair Value price of $0.70 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CRDL ($1.76) is not significantly undervalued (149.86%) relative to our estimate of its Fair Value price of $0.70 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CRDL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CRDL due diligence checks available for Premium users.
Be the first to know about important CRDL news, forecast changes, insider trades & much more!
CRDL News
Valuation
CRDL fair value
Fair Value of CRDL stock based on Discounted Cash Flow (DCF)
Price
$1.76
Fair Value
$0.70
Overvalued by
149.86%
CRDL ($1.76) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CRDL ($1.76) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CRDL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CRDL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-5.43x
Industry
46.47x
Market
41x
CRDL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.54x
Industry
2.04x
CRDL is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CRDL's financial health
Profit margin
Revenue
$0.0
Net Income
-$5.7M
Profit Margin
0%
CRDL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$27.6M
Liabilities
$6.4M
Debt to equity
0.3
CRDL's short-term assets ($26.58M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CRDL's short-term assets ($26.58M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CRDL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.9M
Investing
-$8.0k
Financing
-$10.4k
CRDL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CRDL vs Pharmaceutical Stocks
Cardiol Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.